AR040599A1 - Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad - Google Patents

Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad

Info

Publication number
AR040599A1
AR040599A1 AR20030102575A ARP030102575A AR040599A1 AR 040599 A1 AR040599 A1 AR 040599A1 AR 20030102575 A AR20030102575 A AR 20030102575A AR P030102575 A ARP030102575 A AR P030102575A AR 040599 A1 AR040599 A1 AR 040599A1
Authority
AR
Argentina
Prior art keywords
macular degeneration
patients
age
protection
related macular
Prior art date
Application number
AR20030102575A
Other languages
English (en)
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AR040599A1 publication Critical patent/AR040599A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)

Abstract

Métodos para prevenir la pérdida de la agudeza visual asociada con la degeneración macular mediante la administración yuxtaescleral de acetato de anecortave o su alcohol. La presente presenta asimismo métodos para mantener la agudeza visual en una persona que sufre de AMD y para inhibir el desarrollo de lesiones asociado con AMD.
AR20030102575A 2002-08-05 2003-07-17 Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad AR040599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40122002P 2002-08-05 2002-08-05

Publications (1)

Publication Number Publication Date
AR040599A1 true AR040599A1 (es) 2005-04-13

Family

ID=31495940

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102575A AR040599A1 (es) 2002-08-05 2003-07-17 Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad

Country Status (17)

Country Link
US (2) US20060166956A1 (es)
EP (1) EP1539182A4 (es)
JP (1) JP2005535691A (es)
KR (1) KR20050026510A (es)
CN (1) CN1674913A (es)
AR (1) AR040599A1 (es)
AU (1) AU2003281817A1 (es)
BR (1) BR0313546A (es)
CA (1) CA2494211A1 (es)
DE (1) DE03742226T1 (es)
ES (1) ES2244361T1 (es)
MX (1) MXPA05000773A (es)
PL (1) PL375024A1 (es)
RU (1) RU2322239C2 (es)
TW (1) TW200410699A (es)
WO (1) WO2004012742A1 (es)
ZA (1) ZA200500731B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166956A1 (en) * 2002-08-05 2006-07-27 Jerdan Janice A Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
ZA200505990B (en) * 2003-02-20 2006-12-27 Alcon Inc Formulations of glucocorticoids to treat pathologic ocular angiogenesis
US20070059381A1 (en) * 2003-06-20 2007-03-15 Barker Ronnie C Treatment of amd with combination of ingredients
JP2007506678A (ja) * 2003-09-23 2007-03-22 アルコン，インコーポレイテッド 注入のためのトリアムシノロンアセトアニドおよび酢酸アネコルタブの処方物
US7257366B2 (en) * 2003-11-26 2007-08-14 Osmosis Llc System and method for teaching a new language
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7758778B2 (en) * 2005-09-07 2010-07-20 Southwest Research Institute Methods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
ZA200903649B (en) * 2006-12-18 2010-08-25 Alcon Res Ltd Devices and methods for ophthalmic drug delivery
CN101759741B (zh) * 2008-11-06 2013-01-09 天津金耀集团有限公司 一种化合物及其在制备治疗血管新生的药物中的应用
CN101923856B (zh) 2009-06-12 2012-06-06 华为技术有限公司 语音识别训练处理、控制方法及装置
EP2817031A4 (en) * 2012-02-22 2015-08-05 Tufts College COMPOSITIONS AND METHODS FOR OCULAR DELIVERY OF A THERAPEUTIC AGENT
RU2489146C1 (ru) * 2012-07-11 2013-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения "сухой" формы возрастной макулярной дегенерации

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876250A (en) * 1988-10-31 1989-10-24 Alcon Laboratories, Inc. Methods for controlling ocular hypertension with angiostatic steroids
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5679666A (en) * 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ES2231257T3 (es) * 1999-10-21 2005-05-16 Alcon Inc. Dispositivo para la administracion de farmacos.
US20060166956A1 (en) * 2002-08-05 2006-07-27 Jerdan Janice A Use of anecortave acetate for the protection of visual acuity in patients with age related macular degeneration
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis

Also Published As

Publication number Publication date
PL375024A1 (en) 2005-11-14
JP2005535691A (ja) 2005-11-24
RU2005106234A (ru) 2005-08-10
US20040127472A1 (en) 2004-07-01
DE03742226T1 (de) 2006-03-09
MXPA05000773A (es) 2005-04-19
CA2494211A1 (en) 2004-02-12
KR20050026510A (ko) 2005-03-15
TW200410699A (en) 2004-07-01
WO2004012742A1 (en) 2004-02-12
AU2003281817A1 (en) 2004-02-23
CN1674913A (zh) 2005-09-28
EP1539182A1 (en) 2005-06-15
US20060166956A1 (en) 2006-07-27
ES2244361T1 (es) 2005-12-16
BR0313546A (pt) 2005-07-12
RU2322239C2 (ru) 2008-04-20
EP1539182A4 (en) 2010-01-20
ZA200500731B (en) 2006-08-30

Similar Documents

Publication Publication Date Title
AR040599A1 (es) Uso de acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular relacionada con la edad
TW200600117A (en) Preparation for oral administration
CU23980B1 (es) Formulación liposomal y proceso para la preparación del mismo
BRPI0608297A2 (pt) composições de lipossomos
HK1089376A1 (en) Formulation for use in the prevention and treatment of carbohydrate induced ; diseases and conditions
RS52651B (en) PHARMACEUTICAL COMPOSITION CONTAINING GESTAGENS AND / OR ESTROGENS AND 5-METHYL- (6S) -TETRAHYDROPHOLATE
BR0107535A (pt) Uso de carotenóides e forma de dosagem unitária destes
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
UY27342A1 (es) Agente anticolinérgico cristalino, procedimiento para su preparación y su utilización para la preparación de un medicamento
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
SI1781296T1 (sl) Kinazolinski derivati in njihova uporaba pri zdravljenju trombocitemije
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
HUP0400548A2 (hu) Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
JP2005535691A5 (es)
WO2007128564A3 (en) Use of a compound with rankl activity
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
BRPI0407742A (pt) uso de glicocorticóides para preparação de formulação utilizáveis no tratamento de angiogênese ocular patológica, bem como formulção assim obtida
HK1088926A1 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations
AR059126A1 (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
BRPI0411427A (pt) formulações de agentes antiinflamatórios não-esteróides para o tratamento de angiogênese ocular patológica

Legal Events

Date Code Title Description
FB Suspension of granting procedure